April 4, 2025
Headlines

Biotech

AusperBio Secures $37 Million Series A Funding to Accelerate Development of Hepatitis B Therapy

Editor04 mins

AusperBio Therapeutics, Inc., a pioneering biotechnology firm focused on targeted oligonucleotide therapies for chronic hepatitis B (CHB), has announced the successful completion of a $37 million Series A financing round. This funding, spearheaded by existing investor InnoPinnacle Fund and bolstered by new investors including Yuanbio Venture Capital, Qiming Venture Partners, Hankang Capital, and Genesis Capital,…

Read More

Element Biosciences Secures $277 Million to Propel Innovation in DNA Sequencing and Multi-Omics

Editor05 mins

Element Biosciences, a trailblazer in advancing scientific discovery through groundbreaking technologies, has announced a significant milestone in its journey of innovation. The company has successfully raised over $277 million in Series D funding, underscoring its pivotal role in revolutionizing DNA sequencing and multi-omics technologies. This latest round, led by Wellington Management and supported by a…

Read More

HepaRegeniX Secures €15 Million Series C Funding to Propel Clinical Development of HRX-215 for Liver Regeneration

Editor04 mins

HepaRegeniX GmbH, a pioneering clinical-stage biotechnology firm specializing in regenerative therapies for liver diseases, has announced the successful closure of a Series C funding round totaling €15 million. Led by Vesalius Biocapital IV and supported by existing investors including Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds (HTGF), this investment will accelerate the…

Read More

Pan Cancer T Secures €4.25 Million to Advance Groundbreaking T Cell Therapies

Editor04 mins

Pan Cancer T B.V., a pioneering biotech firm based in Rotterdam, the Netherlands, has successfully concluded a Seed Extension round, securing €4.25 million. This investment round includes participation from new investor InnovationQuarter, alongside continued support from existing backers such as Van Herk Ventures, Thuja Capital, Swanbridge Capital, and Erasmus MC O&O Holdings, bringing Pan Cancer…

Read More

Apriori Bio Receives $1.1M Funding from CEPI to Advance AI Platform for Virus Protection

Editor04 mins

Apriori Bio, a pioneering biotechnology firm, has secured a significant funding injection of US $1.1 million from CEPI (Coalition for Epidemic Preparedness Innovations) to propel its cutting-edge artificial intelligence platform, Octavia™. Designed to safeguard against rapidly-evolving viral threats, Octavia™ employs advanced machine learning to predict and counteract virus mutations, crucial for developing variant-resilient vaccines. Octavia™…

Read More

Granza Bio Secures $7M+ Seed Funding to Propel Advanced Cancer Treatments and Genetic Medicines

Editor06 mins

Granza Bio Corporation, a trailblazing biotechnology firm rooted in pioneering therapeutic delivery platforms, has successfully concluded an oversubscribed $7.14 million Seed funding round. The funding was led by prominent investors including Felicis and Refactor, alongside participation from Y Combinator and a consortium of esteemed angel investors. Established in 2024 by distinguished researchers from the University…

Read More

Zhiyi Biotech Reports Successful Phase I Results for SK10 in Chemotherapy-induced Diarrhea Treatment

Editor03 mins

Zhiyi Biotech, a pioneering clinical-stage biotech specializing in live biotherapeutic products (LBPs), has achieved significant milestones with its latest clinical trial results for SK10. The Phase I study, conducted in the United States, has demonstrated promising outcomes in the treatment of chemotherapy-induced diarrhea (CID) using SK10, an innovative heat-killed Bacteroides fragilis product. The randomized, double-blind,…

Read More

Myricx Bio Secures £90 Million Series A Funding to Revolutionize Cancer Treatment with Novel NMTi-ADC Therapeutics

Editor05 mins

A new wave of hope is washing over the oncology field with Myricx Bio’s impressive £90 million ($114 million) Series A funding. This UK biotech company, unlike its peers, isn’t taking an incremental step forward. Instead, they’re wielding a whole new weapon in the fight against cancer: N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugates (ADCs). The significance…

Read More

Beacon Therapeutics Raises $170 Million to Propel Ophthalmic Gene Therapy Innovations

Editor04 mins

Beacon Therapeutics, a pioneering ophthalmic gene therapy company dedicated to combating blinding retinal diseases, has secured $170 million in Series B funding, marking a significant stride towards advancing its transformative treatments. Led by Forbion and supported by existing investors Syncona and Oxford Science Enterprises, alongside newcomers TCGX and Advent Life Sciences, this funding round will…

Read More

Rejuvenate Bio Secures $4M Funding from CIRM to Advance Breakthrough Gene Therapy for Rare Heart Condition

Editor05 mins

Rejuvenate Bio, a pioneering biotechnology firm specializing in gene therapies, announced today the reception of a $4 million grant from the California Institute for Regenerative Medicine (CIRM) to propel the development of its innovative gene therapy, RJB-0402, aimed at treating desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM). Desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM) is…

Read More